AU2014360344B2 - Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis - Google Patents

Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis Download PDF

Info

Publication number
AU2014360344B2
AU2014360344B2 AU2014360344A AU2014360344A AU2014360344B2 AU 2014360344 B2 AU2014360344 B2 AU 2014360344B2 AU 2014360344 A AU2014360344 A AU 2014360344A AU 2014360344 A AU2014360344 A AU 2014360344A AU 2014360344 B2 AU2014360344 B2 AU 2014360344B2
Authority
AU
Australia
Prior art keywords
exosomes
cancer
cell
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014360344A
Other languages
English (en)
Other versions
AU2014360344A1 (en
Inventor
Raghu Kalluri
Sonia MELO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2014360344A1 publication Critical patent/AU2014360344A1/en
Application granted granted Critical
Publication of AU2014360344B2 publication Critical patent/AU2014360344B2/en
Priority to AU2019200573A priority Critical patent/AU2019200573A1/en
Priority to AU2019201290A priority patent/AU2019201290A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
AU2014360344A 2013-12-04 2014-12-04 Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis Ceased AU2014360344B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019200573A AU2019200573A1 (en) 2013-12-04 2019-01-30 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
AU2019201290A AU2019201290A1 (en) 2013-12-04 2019-02-25 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911863P 2013-12-04 2013-12-04
US61/911,863 2013-12-04
PCT/US2014/068630 WO2015085096A1 (en) 2013-12-04 2014-12-04 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2019200573A Division AU2019200573A1 (en) 2013-12-04 2019-01-30 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
AU2019201290A Division AU2019201290A1 (en) 2013-12-04 2019-02-25 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Publications (2)

Publication Number Publication Date
AU2014360344A1 AU2014360344A1 (en) 2016-07-14
AU2014360344B2 true AU2014360344B2 (en) 2018-11-29

Family

ID=53274132

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014360344A Ceased AU2014360344B2 (en) 2013-12-04 2014-12-04 Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
AU2019200573A Abandoned AU2019200573A1 (en) 2013-12-04 2019-01-30 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
AU2019201290A Withdrawn AU2019201290A1 (en) 2013-12-04 2019-02-25 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019200573A Abandoned AU2019200573A1 (en) 2013-12-04 2019-01-30 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
AU2019201290A Withdrawn AU2019201290A1 (en) 2013-12-04 2019-02-25 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Country Status (13)

Country Link
US (3) US9921223B2 (https=)
EP (1) EP3076949B1 (https=)
JP (3) JP2017501694A (https=)
AU (3) AU2014360344B2 (https=)
CA (1) CA2936100A1 (https=)
DK (1) DK3076949T3 (https=)
HR (1) HRP20192131T1 (https=)
HU (1) HUE046489T2 (https=)
LT (1) LT3076949T (https=)
NZ (1) NZ721720A (https=)
SI (1) SI3076949T1 (https=)
WO (1) WO2015085096A1 (https=)
ZA (1) ZA201604468B (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2006116362A2 (en) 2005-04-25 2006-11-02 The Trustees Of Boston University Structured substrates for optical surface profiling
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US11180812B2 (en) 2012-08-17 2021-11-23 Cornell University Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
CN105264092B (zh) 2013-03-15 2019-02-22 得克萨斯州大学系统董事会 用于诊断和疗法的外来体中的miRNA生物发生
JP2017501694A (ja) * 2013-12-04 2017-01-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
CR20160307A (es) 2013-12-20 2016-11-08 Advanced Regen Medical Tech Llc Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
US10844436B2 (en) * 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
US11339441B2 (en) * 2015-05-12 2022-05-24 The Research Foundation For The State University Of New York Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
WO2016201064A1 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CN114217058A (zh) 2015-09-22 2022-03-22 波士顿大学董事会 纳米囊泡的多重表型分析
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
JP7033082B2 (ja) * 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド 表面マーカーを有するエキソソームの検出
RU2018136151A (ru) * 2016-03-15 2020-04-15 Кодиак Байосайнсиз, Инк. Терапевтические мембранные везикулы
EP3436081A4 (en) 2016-04-29 2019-07-24 Advanced Regen Medical Technologies, LLC Microrna compositions and methods of making and using same
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2017223186A1 (en) * 2016-06-21 2017-12-28 Nant Holdings Ip, Llc Exosome-guided treatment of cancer
CN106124282B (zh) 2016-07-26 2019-07-16 广州海力特生物科技有限公司 一种叠层离心过滤分离提取外泌体的方法
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN110650728B (zh) * 2017-03-21 2023-06-23 埃索普罗瑟医疗有限公司 含有用于治疗的肿瘤抑制蛋白的天然细胞衍生的囊泡
GB2560897A (en) 2017-03-23 2018-10-03 Lotvall Jan Tissue-derived extracellular vesicles and their use as diagnostics
EP4699658A2 (en) 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107338306A (zh) * 2017-07-23 2017-11-10 嘉兴允英医学检验有限公司 一种用于GPC1mRNA表达检测的试剂盒
JP2020529477A (ja) * 2017-08-04 2020-10-08 シーダーズ—シナイ メディカル センター がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
WO2019094692A2 (en) 2017-11-09 2019-05-16 The Trustees Of The University Of Pennsylvania Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
WO2019109077A1 (en) 2017-12-01 2019-06-06 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer
CA3084821A1 (en) 2017-12-15 2019-06-20 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using exosomes-associated gene editing
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
AU2018394238A1 (en) * 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
US10717981B2 (en) 2018-01-18 2020-07-21 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
JP7813099B2 (ja) * 2018-03-28 2026-02-12 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 治療用物質を標的送達するためのエキソソームの使用法
EP3775258A4 (en) * 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
CN112236130A (zh) * 2018-04-09 2021-01-15 得克萨斯州大学系统董事会 使用外排体对癌基因的治疗性靶向
EP3788150A4 (en) * 2018-05-04 2022-01-26 Sigma-Aldrich Co. LLC PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
EP3803332A1 (en) 2018-06-01 2021-04-14 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
IL269897B2 (en) 2018-11-15 2023-08-01 Sternum Ltd Implementing control flow correctness verification in code intermediate files
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
WO2020146390A1 (en) 2019-01-09 2020-07-16 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
US20220113313A1 (en) * 2019-02-01 2022-04-14 NanoView Biosciences, Inc. Systems and methods for vesicle cargo labeling and detection
AU2020218358A1 (en) * 2019-02-08 2021-08-26 Board Of Regents, The University Of Texas System Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes
CN114080232A (zh) * 2019-03-21 2022-02-22 科迪亚克生物科学公司 用于疫苗递送的细胞外囊泡
WO2020219699A1 (en) * 2019-04-23 2020-10-29 Children's Medical Center Corporation Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb)
EP4013392B1 (en) 2019-09-13 2026-04-29 Exocure Sweden AB Use of ghost nanovesicles as therapeutics
JP7462452B2 (ja) * 2020-03-27 2024-04-05 株式会社日立製作所 培養細胞の分化レベルを評価するための評価装置および評価方法、並びに自動細胞培養システム
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
US20230340606A1 (en) * 2021-09-09 2023-10-26 The Regents Of The University Of California Extracellular repetitive rna biomarkers of mutant kras cancers
WO2023081099A1 (en) * 2021-11-02 2023-05-11 Daniel Kim Extracellular rna signatures of mutant kras(g12c) cancers
WO2023210644A1 (ja) * 2022-04-26 2023-11-02 国立大学法人東京大学 がん細胞由来細胞外小胞群の単離濃縮方法、分析方法、薬剤選択方法、キット、及び抗がん剤
US20250290919A1 (en) * 2022-05-06 2025-09-18 The Trustees Of The University Of Pennsylvania Ultrasensitive single extracellular vesicle detection using high throughput droplet digital enzyme-linked immunosorbent assay
WO2024047441A1 (en) * 2022-09-01 2024-03-07 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method for monitoring tumor burden in subjects during therapeutic intervention
WO2024073671A1 (en) * 2022-09-30 2024-04-04 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196426A1 (en) * 2008-02-01 2010-08-05 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US20120196285A1 (en) * 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
US9777042B2 (en) * 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
US9309559B2 (en) * 2013-04-15 2016-04-12 Albert Einstein College Of Medicine, Inc. Simultaneous extraction of DNA and RNA from FFPE tissues
JP2017501694A (ja) * 2013-12-04 2017-01-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196426A1 (en) * 2008-02-01 2010-08-05 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GÖRAN K. RONQUIST ET AL, "Prostasomes are heterogeneous regarding size and appearance but affiliated to one DNA-containing exosome family", PROSTATE, 2012, 72(16):1736-1745 *
JIN CAI ET AL, "Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells", JOURNAL OF MOLECULAR CELL BIOLOGY, 2013, 5(4):227-238 *

Also Published As

Publication number Publication date
US20200200755A1 (en) 2020-06-25
US10598665B2 (en) 2020-03-24
HUE046489T2 (hu) 2020-03-30
JP2021177760A (ja) 2021-11-18
AU2014360344A1 (en) 2016-07-14
LT3076949T (lt) 2019-12-10
US9921223B2 (en) 2018-03-20
AU2019200573A1 (en) 2019-02-21
SI3076949T1 (sl) 2020-01-31
WO2015085096A1 (en) 2015-06-11
ZA201604468B (en) 2024-01-31
EP3076949A4 (en) 2017-11-22
CA2936100A1 (en) 2015-06-11
DK3076949T3 (da) 2019-11-25
NZ721720A (en) 2022-04-29
JP7138372B2 (ja) 2022-09-16
US20170059572A1 (en) 2017-03-02
US20180045728A1 (en) 2018-02-15
HRP20192131T1 (hr) 2020-02-21
EP3076949B1 (en) 2019-09-04
JP2017501694A (ja) 2017-01-19
AU2019201290A1 (en) 2019-03-14
JP2019198327A (ja) 2019-11-21
EP3076949A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
US10598665B2 (en) Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
AU2019243179B2 (en) Use of exosomes for targeted delivery of therapeutic agents
AU2018386215B2 (en) Methods and compositions for treating cancer using exosomes-associated gene editing
US20210369858A1 (en) Use of exosomes for targeted delivery of therapeutic agents
AU2019255765B2 (en) Therapeutic modulation of tumor suppressors using exosomes
US20210024936A1 (en) Therapeutic targeting of oncogenes using exosomes
US20220163532A1 (en) Nuclear-derived exosomes and methods of use thereof
HK1227707B (en) Method for isolating cancer cell-derived exoxomes
HK1227707A1 (en) Method for isolating cancer cell-derived exoxomes
US20220016205A1 (en) Methods of overcoming resistance to immune checkpoint inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired